Laham, Y., Ringelstein-Harlev, S., Kurnik, D., Fineman, R., Yehudai-Ofir, D., Bonstein, L., Setter-Marco, N., Braun, E., Ghersin, I., Zuckerman, T. and Beyar-Katz, O. (2020) “High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2024.286714.